CD274 and lung carcinoma: Additionally, silibinin-treated samples showed significant inhibition of STAT5/PD-L1 binding (Figure 6D), clearly suggesting the role of the STAT5/PD-L1 signaling cascade in the anticancer activity of silibinin against NSCLC cells that could suggest silibinin as an immunotherapeutic drug against lung cancer cells.